Clovis Oncology, Inc. (NASDAQ:CLVS) Reviewed By Analysts

Clovis Oncology, Inc. (NASDAQ:CLVS) Reviewed By Analysts

Finally, Vanguard Group Inc. boosted its stake in shares of Clovis Oncology by 25.3% in the first quarter.

Stock has got outperform rating from 18 of Thomson Reuters analysts whereas 2 given HOLD rating to the stock. Therefore 79% are positive. According to the past 5 years report, the company on average reported -32.30% year-over-year EPS growth and sales growth was recorded at -8.50%.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. The firm earned "Buy" rating on Friday, August 5 by Suntrust Robinson. The firm has "Hold" rating by Deutsche Bank given on Wednesday, July 22. The firm has "Overweight" rating given on Friday, January 13 by Morgan Stanley. They now have a $75.00 price objective on the biopharmaceutical company's stock. Analysts are forecasting earnings of $-1.2 on a per share basis this quarter.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The stock's market capitalization is 2.68B, it has a 52-week low of 11.57 and a 52-week high of 74.94. "If approved, Rubraca would have the broadest label of any PARP inhibitor in ovarian cancer. which we think should bode well for the commercial uptake of the drug", Schmidt said, calling the company a prime takeout candidate. It now has negative earnings.

The U.S. Food and Drug Administration last December granted Rubraca accelerated approval in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite two or more rounds of chemotherapy.

Koepka's trip around the world leads to major title at home
Only Tiger Woods (-12, 2000), Rory McIIroy (-16, 2011) and Martin Kaymer (-9, 2014) have finished with a score of -9 or lower. Open wasn't lost, it was won by a 27-year-old Florida native who had only won one other PGA tournament.

Investors sentiment decreased to 1.03 in Q4 2016. It dropped, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. As of the end of the quarter Fny Partners Fund Lp had acquired a total of 10 shares growing its position 66.7%. Artal Grp owns 0.05% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 50,000 shares.

Columbia Wanger Asset Management Ltd Liability Corporation has 189,958 shares for 0.12% of their portfolio. EAM Investors LLC owned approximately 0.13% of Clovis Oncology as of its most recent SEC filing. Piper Jaffray Companies set a $77.00 price objective on shares of Clovis Oncology and gave the company a "buy" rating in a research report on Tuesday, March 14th. Bluemountain Cap Mgmt Ltd Limited Liability Company holds 2,748 shares. Oakbrook Invests Ltd Liability Corp reported 0.03% of its portfolio in ABIOMED, Inc. California-based Wells Fargo And Mn has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). State Street Corp increased its position in shares of Clovis Oncology by 93.7% in the fourth quarter. On average, equities research analysts expect that Clovis Oncology will post ($4.95) EPS for the current fiscal year. Pictet Asset Management Limited holds 195,285 shares or 0.03% of its portfolio. Proshare Advsrs reported 30,597 shares or 0.02% of all its holdings. It was reported on Jun, 19 by

Since March 15, 2017, it had 0 buys, and 3 selling transactions for $528,600 activity.

The share price of the company (NASDAQ:CLVS) was up +0.45% during the last trading session, with a high of 60.74 and the volume of Clovis Oncology, Inc. shares traded was 2202374. The Company's products include precision robotic solutions; gas delivery systems; a range of industrial and automation production equipment products; subsystems that includes wafer cleaning sub-systems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. It has a 15.94 P/E ratio. The stock increased 0.36% or $0.51 on June 16, reaching $143.39. About 632 shares traded. (NASDAQ:ABMD) has risen 40.97% since June 19, 2016 and is uptrending. It has outperformed by 304.16% the S&P500.

Related Articles